4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Novartis India Limited (NOVARTIND) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Mumbai, India with about 57 employees. Its market capitalization is roughly ₹51 billion. In the fiscal year ended 2026-03-31, NOVARTIND reported ₹3.5B in revenue and ₹932M in net income.
Novartis India Limited is involved in the pharmaceutical business in India. The company offers therapeutic products in the areas of bone and pain products under the Voveran brand; transplantation immunology products under the Simulect, Certican, Sandimmun, Neoral, and Myfortic brands.
Interactive charts & full statements →
| Income statement | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Revenue | ₹3.5B | ₹3.6B | ₹3.3B | ₹3.7B | — |
| Gross Profit | ₹1.5B | ₹1.5B | ₹1.3B | ₹1.6B | — |
| Operating Income (EBIT) | ₹944M | ₹942M | ₹653M | ₹693M | — |
| Net Income | ₹932M | ₹1.0B | ₹852M | ₹1.0B | — |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Total Revenue | ₹1.0B | ₹906M | ₹859M | — | ₹876M | ₹839M |
| Gross Profit | ₹481M | ₹384M | ₹370M | — | ₹408M | ₹346M |
| Operating Income (EBIT) | ₹345M | ₹201M | ₹218M | — | ₹267M | ₹232M |
| Net Income | ₹322M | ₹252M | ₹161M | — | ₹276M | ₹293M |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Dividends Paid | (₹617M) | (₹617M) | (₹1.2B) | (₹247M) | — |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Assets | ₹9.8B | ₹9.5B | ₹9.2B | ₹9.8B | — |
| Total Liabilities | ₹1.6B | ₹1.6B | ₹1.8B | ₹2.1B | — |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NOVARTIND viewer.
About TickerBase · Data methodology & sources · Privacy · Terms